Haemonetics Corporation has announced its intention to acquire Vivasure Medical Limited, an Irish medical device company, in a deal worth up to 185 million euros. This strategic move aims to solidify Haemonetics' position in the rapidly expanding structural heart and endovascular procedures markets. The acquisition will integrate Vivasure's innovative PerQseal Elite system into Haemonetics' interventional technology portfolio, addressing the increasing demand for advanced large-bore vascular access solutions.
The agreement includes an upfront payment of 100 million euros (approximately $117 million), with potential additional payments of up to 85 million euros contingent on achieving future sales growth and operational milestones. Haemonetics plans to finance this transaction using its existing cash reserves, underscoring its commitment to investing in differentiated technologies within high-growth procedural areas. This acquisition is anticipated to enhance patient safety and streamline clinical workflows in complex cardiovascular interventions.
Vivasure's flagship product, the PerQseal Elite system, offers a unique approach to closing large-bore arterial and venous access sites from within the vessel. This system utilizes a proprietary bioabsorbable patch, capable of managing access sizes up to 26F. Its fully absorbable and sutureless design is expected to significantly reduce complications and improve procedural efficiency for healthcare professionals.
The PerQseal Elite has already received CE Mark approval in Europe for both arterial and venous indications. Furthermore, Vivasure submitted a Premarket Approval (PMA) application to the U.S. FDA in 2025 for the arterial version of its device, indicating a strong regulatory pathway and potential for broader market adoption. Clinical data from the multicenter ELITE arterial study demonstrated excellent safety and efficacy, reporting no major complications within 30 days, an immediate median time to hemostasis, and eliminating the need for a pre-closure technique.
Ken Crowley, Vice President & General Manager of Interventional Technologies at Haemonetics, emphasized the strategic importance of this acquisition. He stated that integrating Vivasure's clinically proven technology would expand Haemonetics' comprehensive range of closure devices, strengthening its presence in the large-bore closure market and enhancing its impact on fast-growing structural heart and endovascular procedures. Haemonetics reported a robust cash position of $296.4 million as of September 27, 2025, providing ample liquidity for the acquisition.
Looking ahead, Haemonetics is scheduled to release its third-quarter fiscal 2026 financial results on February 5. This upcoming report is expected to offer further insights into the company’s capital deployment strategies and its plans for integrating Vivasure Medical into its operations. On Thursday, Haemonetics shares saw a 1.25% increase, closing at $84.04, nearing its 52-week high of $87.32, according to market data.
This strategic acquisition represents a significant step for Haemonetics in expanding its technological capabilities and market reach within the medical device sector. By incorporating Vivasure's innovative vascular closure solutions, Haemonetics aims to deliver enhanced clinical outcomes and operational efficiencies for patients undergoing intricate cardiovascular procedures, reinforcing its commitment to advancing healthcare technology and improving patient care globally.